Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers. Sep 2011 - Cancer Immunol. Immunother.; 60(10):1432-0851 [PMID:21638124] [Shindo G] [Endo T] [Onda M] [Miyamoto Y] [Kaneko T] [Goto S]
Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. Nov 2005 - Anticancer Res.; 25(6A):0250-7005 [PMID:16302730] [Kaneko T] [Goto S] [Kato A] [Akeyama A] [Tomonaga M] [Fujimoto K] [Miyamoto Y] [Eriguchi M] [Egawa K]
Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma. Nov 2005 - Anticancer Res.; 25(6A):0250-7005 [PMID:16302734] [Goto S] [Kaneko T] [Miyamoto Y] [Eriguchi M] [Kato A] [Akeyama T] [Fujimoto K] [Tomonaga M] [Egawa K]
A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Mar 2003 - Cancer Immunol. Immunother.; 52(3):0340-7004 [PMID:12649744] [Iwashita Y] [Tahara K] [Goto S] [Sasaki A] [Kai S] [Seike M] [Chen CL] [Kawano K] [Kitano S]
